TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A paper in The Lancet Healthy Longevity argues that sarcopenia should be understood as a problem involving the aging motor system, including the brain, nerves and muscles, rather than muscle loss alone. The authors say this could broaden assessment and research, but the proposed measures have not yet been shown to outperform existing screens or improve outcomes.
Researchers writing in The Lancet Healthy Longevity argue that age-related weakness and mobility loss should be understood as more than muscle decline, proposing that sarcopenia involves the aging motor system—from the brain and spinal cord to nerves and muscles. The proposal could change how clinicians assess older adults, but its suggested tests have not yet been shown to improve outcomes or outperform existing screening methods.
The paper, by Lucas B. R. Orssatto and colleagues, says the clinical definition of sarcopenia has already moved beyond muscle size. Measures such as grip strength, walking speed and chair stands are used because they predict falls, disability and death better than muscle mass does. The authors argue that explanations and treatment approaches have not kept pace with that change: sarcopenia is still commonly treated as a disease of muscle, with weakness assumed to follow muscle wasting.
The authors point to evidence that muscle loss accounts for only a modest proportion of strength decline in older adults. People with similar muscle amounts can have different strength and mobility, while exercise can improve those abilities even without a measurable increase in muscle mass. They propose that aging also affects movement planning, the reliability and strength of nerve signals, balance and awareness of body position.
The researchers suggest clinicians assess more than whether a person can complete a movement. Examples include how quickly someone rises from a chair, steadiness during sustained effort, hand dexterity and whether walking changes while talking. They also call for attention to rapid or uneven weakness and medication review, since sedative and anticholinergic drugs can blunt motor drive. These are proposals for assessment, not established replacements for current screening.
Broader Checks for Everyday Mobility
The proposed shift matters because weakness can affect falls, disability and independence, outcomes that muscle-building alone may not address. If the motor system contributes to an individual’s decline, identifying the relevant problem could help clinicians choose assessments and interventions suited to that person rather than focusing mainly on muscle mass.
The Australian context gives the issue practical weight. The source report says Australia recorded 253,800 fall-related hospitalizations in 2024–25. It also reports 6,722 deaths following falls in the preceding year and estimates fall injuries cost the health system $5.4 billion. These figures describe different time periods and measures; they do not establish that the paper’s proposed approach would reduce falls or costs.
For now, the paper is a research and clinical framework rather than proof of a new treatment. The authors say the approach could redirect investment toward interventions that improve strength, movement and daily function, but that possibility needs testing. The practical question is whether broader motor-system assessments can identify risks or guide care more effectively than existing tools.
Products Worth Considering
BowFlex Results Series SelectTech 552 Adjustable Dumbbell
Bowflex SelectTech 840 Adjustable Kettlebell
Withings Sleep Under-Mattress Sleep Tracking Pad
As an affiliate, we earn on qualifying purchases.
How Sarcopenia Is Assessed
Sarcopenia refers to substantial loss of muscle, strength and physical function associated with aging. The source report says it affects up to 29% of community-dwelling older adults, with higher rates in hospitals, residential elder care and among people with frailty or multiple health conditions. The figure is an estimate for community-dwelling older adults, not a rate for every setting.
Earlier in 2026, the Australian Journal of General Practice published a proposed algorithm for screening, assessing and managing poor muscle health in primary care. The Lancet Healthy Longevity paper asks whether that clinical work should also account more directly for the nerves and other parts of the motor system. Its authors set out a five-point agenda for international groups that develop diagnostic criteria; the source report does not detail each point.
The distinction is between the measures used to identify impaired function and the explanation for it. Grip strength, gait speed and chair stands can indicate a problem, but the authors say muscle quantity alone may not explain why two people perform differently. Their paper calls for testing a wider account of how movement is produced.
“We propose that sarcopenia is better understood as a disease of the aging motor system.”
— Lucas B. R. Orssatto and colleagues, authors of the paper in The Lancet Healthy Longevity
Evidence Needed Before Clinical Change
It remains unclear whether the proposed measures can detect clinically meaningful problems better than current screens, improve patient outcomes or be cost-effective. The source report says these benefits have not been demonstrated. It also notes that neuromuscular expertise is not equally available across primary care settings.
The paper argues for a broader model, but the source material does not report a trial showing that motor-system-focused treatment prevents falls or preserves independence better than existing care. Nor does it establish which tests should be adopted, how they should be scored, or which patients would benefit most. The reported Australian fall figures describe the scale of the problem; they do not show that this proposed framework will change those numbers.
Validation and Trials Ahead
The authors call for practical tests to be validated, guidelines to support a staged assessment approach, and clinical trials that measure nerve as well as muscle outcomes. These steps would help determine whether the framework can be applied in routine care and whether it changes treatment decisions or everyday function.
International working groups that write sarcopenia diagnostic criteria are a potential audience for the paper’s proposed agenda. The source material does not give a timetable for revisions or identify a specific next meeting or trial. Until further evidence is available, the broader assessment remains a proposal rather than a confirmed change in clinical standards.
Key Questions
What is sarcopenia?
Sarcopenia is substantial loss of muscle, strength and physical function associated with aging. The paper argues that muscle loss alone does not explain all age-related weakness.
What does the motor-system proposal include?
It includes the brain, spinal cord, nerves and muscles involved in producing movement, along with functions such as balance and awareness of body position.
Are clinicians being told to replace current tests?
No. The paper proposes additional ways to assess movement, but the authors say these measures have not been shown to outperform existing screens on outcomes or cost.
What evidence do the authors say is needed?
They call for validation of practical tests, staged clinical guidance and trials that measure nerve and muscle outcomes as well as strength and daily function.
Source: medicalxpress.com
